Given that increased AR expression has been associated with poorer prognosis in some of these cancers (early-stage hepatocellular carcinoma and colon cancer), these results suggest that these pathways may serve as effective therapeutic targets across multiple cancers, including head and neck cancer and breast cancer [56,57]. This evidence concerns the gene AR and colonic neoplasm.